RBC Capital Reiterates Outperform on Regeneron Pharmaceuticals, Maintains $1260 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has reiterated its Outperform rating for Regeneron Pharmaceuticals, maintaining a price target of $1260.
October 22, 2024 | 5:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating for Regeneron Pharmaceuticals, maintaining a price target of $1260. This suggests confidence in the company's future performance.
The reiteration of an Outperform rating and a high price target by RBC Capital indicates strong confidence in Regeneron's future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100